CSOApollo TherapeuticsCambridge, England, United Kingdom
PB0338 - Novel therapeutic antibodies targeting the C-domains of Von Willebrand Factor drives anti-thrombotic efficacy with reduced bleeding risk
Sunday, June 23, 202413:45 – 14:45 ICT
